Rachel Hauritz, PhD, Cofounder, President and CEO, Caribou Biosciences. Rachel was doing PhD research on CRISPR in Jennifer Doudna’s lab at Berkeley before anyone understood its potential. As scientists uncovered more about CRISPR, Doudna and Haurwitz started discussing the commercial possibilities and founded the company in 2011. Since that time, the company has raised $45MM and is a leader in CRISPR therapeutics. Rachel, a self described nerd in high school, became CEO as her first job. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Hear her story and what it’s like to be central to the exciting field of CRISPR. Sponsored by Latham & Watkins.